Global leader in medical device fluid injection systems selects clinivation enterprise solutions for accelerated global market access and comprehensive global regulatory intelligence.
NATICK, MA – June 18, 2013 – Clinivation, Inc. is pleased to announce today that Bayer Healthcare and MEDRAD teams have selected clinivation enterprise solutions for accelerated market access, scalable execution, and comprehensive global regulatory intelligence.
The recent proliferation of new market clearance regulations and processes in the fast-growing international markets presents new challenges of execution: to effectively deliver larger, more complex market clearance portfolios faster than ever before.
In addition, ongoing industry consolidation means that global market clearance operations must now be capable of not only rapidly integrating new product lines and organizations- but also leveraging infrastructure for business growth and lean business performance.
And contemporary corporate governance now requires executives to implement effective market clearance operational controls to mitigate exposure from myriad compliance risks, penalties, fines, and legal costs.
To address the challenges of execution, the clinivation Global Platform enables cross-functional teams to work in scalable global market clearance operations that positions their organization to effectively address an expanded international scope.
Teams have full visibility on their consolidated global market clearance operations- and key performance metrics to find and fix the stall-outs and bottlenecks that trap revenue in inefficient process.
And teams can operate in new markets with access to knowledge and content that is far beyond that which is organic to any department, division, or business unit.
Intuitive dashboards, content unification technology, and streamlined reporting reclaim the team bandwidth that’s now consumed by functioning as a regulatory “help desk,” repeatedly reassembling product dossiers, blindly searching for documentation, and manually preparing routine status reports for senior management.
Enterprise-class systems reclaim the productivity that’s now consumed by the uncertainties of legacy “tracking tools,” home-grown databases, and spreadsheet farms. And integrated architecture accelerates workflow by enabling cross-functional teams to work in synchrony on parallel threads of activity in a manner that properly focuses, builds, and unifies their workflow into tangible, robust market clearance milestones.
Supporting Resources:
For more information on the clinivation Enterprise Solution for On-Demand Global Regulatory Intelligence and Client-Directed Case Research Solutions, please visit the clinivation WorldView homepage.
For more information on the clinivation Enterprise Solution for Global Market Clearance Management, please visit the clinivation Global homepage.
About Bayer Healthcare MEDRAD:
MEDRAD, Inc. develops, markets and services medical devices used to diagnose and treat disease. Its product offerings include fluid injection systems for radiology and cardiology, endovascular devices for the safe treatment of cardiovascular disease, magnetic resonance-compatible accessories and equipment services. The company’s world headquarters is near Pittsburgh, Pennsylvania, in the United States.
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.9 billion (2013), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 56,000 employees (Dec 31, 2013) and is represented in more than 100 countries.
